DK118887D0 - Fremgangsmaade til indvinding af mikrobielt produceret, rekombinant, oploeseligt ricintoxin-a-kaede - Google Patents

Fremgangsmaade til indvinding af mikrobielt produceret, rekombinant, oploeseligt ricintoxin-a-kaede

Info

Publication number
DK118887D0
DK118887D0 DK118887A DK118887A DK118887D0 DK 118887 D0 DK118887 D0 DK 118887D0 DK 118887 A DK118887 A DK 118887A DK 118887 A DK118887 A DK 118887A DK 118887 D0 DK118887 D0 DK 118887D0
Authority
DK
Denmark
Prior art keywords
ricintoxin
recombinant
recovery
soluble
chain
Prior art date
Application number
DK118887A
Other languages
English (en)
Other versions
DK118887A (da
Inventor
Robert Ferris
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK118887D0 publication Critical patent/DK118887D0/da
Publication of DK118887A publication Critical patent/DK118887A/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809Fused cells, e.g. hybridoma

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK118887A 1986-03-06 1987-03-06 Fremgangsmaade til indvinding af mikrobielt produceret, rekombinant, oploeseligt ricintoxin-a-kaede DK118887A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83684886A 1986-03-06 1986-03-06
US06/905,283 US4689401A (en) 1986-03-06 1986-09-09 Method of recovering microbially produced recombinant ricin toxin a chain

Publications (2)

Publication Number Publication Date
DK118887D0 true DK118887D0 (da) 1987-03-06
DK118887A DK118887A (da) 1987-09-07

Family

ID=27125896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK118887A DK118887A (da) 1986-03-06 1987-03-06 Fremgangsmaade til indvinding af mikrobielt produceret, rekombinant, oploeseligt ricintoxin-a-kaede

Country Status (7)

Country Link
US (1) US4689401A (da)
EP (1) EP0237297A1 (da)
AU (1) AU596153B2 (da)
CA (1) CA1308680C (da)
DK (1) DK118887A (da)
FI (1) FI870981L (da)
NO (1) NO870668L (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956453A (en) * 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US4911912A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
EP0419462A4 (en) * 1987-07-17 1991-07-17 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
EP0341304A4 (en) * 1987-11-24 1991-01-30 Genetics Institute, Inc. Improved ricin molecules and ricin toxin conjugates
ATE195142T1 (de) * 1991-02-26 2000-08-15 Zeneca Ltd Fermentationsverfahren zur herstellung von peptiden durch einen wirt
USH1985H1 (en) 1992-01-09 2001-08-07 The United States Of America As Represented By The Secretary Of The Navy Method for detecting biological toxins
US5453271A (en) * 1993-06-28 1995-09-26 The United States Of America As Represented By The Secretary Of The Army Vaccine against ricin toxin
US5437986A (en) * 1994-06-22 1995-08-01 Schering Corporation Extraction of heterologous insoluble proteins from bacteria
DE60039510D1 (de) 1999-05-27 2008-08-28 Us Gov Health & Human Serv Immunokonjugate mit hoher bindungsaffinität
US6869787B2 (en) * 2002-02-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Ricin vaccine and methods of making and using thereof
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
JP5889533B2 (ja) 2008-01-31 2016-03-22 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変された抗体定常ドメイン分子
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
ES2611479T3 (es) 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
ES2678204T3 (es) 2010-07-30 2018-08-09 Medimmune, Llc Método para purificar inmunoconjugados
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
JP6216317B2 (ja) 2011-09-09 2017-10-18 メディミューン リミテッド 抗Siglec−15抗体およびその使用
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP2764025B1 (en) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antibodies against hmw-maa
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014031476A1 (en) 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
JP6553515B2 (ja) 2012-12-20 2019-07-31 メディミューン,エルエルシー 免疫複合体の製造方法
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
JP7269733B2 (ja) 2015-06-12 2023-05-09 レンティジェン・テクノロジー・インコーポレイテッド 操作されたt細胞を用いて癌を処置するための方法
WO2017049296A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
AU2016335848B2 (en) 2015-10-09 2020-12-17 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
CA3035615A1 (en) 2016-09-02 2018-03-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CA3096798C (en) 2017-01-09 2026-02-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for treating cancer with anti-mesothelin immunotherapy
CN112695050B (zh) 2017-03-24 2025-08-08 莱蒂恩技术公司 用于用抗cd33免疫疗法治疗癌症的组合物和方法
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
CA3075915A1 (en) 2017-09-15 2019-03-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19 immunotherapy
WO2019079249A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
JP7448903B2 (ja) 2017-11-03 2024-03-13 レンティジェン・テクノロジー・インコーポレイテッド 抗ror1免疫療法によってがんを処置するための組成物および方法
WO2019126464A2 (en) 2017-12-20 2019-06-27 Lentigen Technology, Inc. Compositions and methods for treating hiv/aids with immunotherapy
WO2020014482A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
WO2020061498A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
CN118581122A (zh) 2018-09-26 2024-09-03 莱蒂恩技术公司 用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
EP3886895A1 (en) 2018-11-30 2021-10-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd38 immunotherapy
AU2020206308B2 (en) 2019-01-08 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
US11969443B2 (en) 2019-03-06 2024-04-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
CN114364801B (zh) 2019-05-30 2024-04-19 莱蒂恩技术公司 用于用抗bcma免疫治疗来治疗癌症的组合物和方法
AU2020299382A1 (en) 2019-07-02 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind EGFRvIII and their use
US12552865B2 (en) 2019-10-22 2026-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
CA3171101A1 (en) 2020-06-22 2021-12-30 Dina SCHNEIDER Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
EP4240397A1 (en) 2020-11-05 2023-09-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
AU2022291120A1 (en) 2021-06-09 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
US20240417446A1 (en) 2021-10-26 2024-12-19 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
CN119907810A (zh) 2022-08-26 2025-04-29 莱蒂恩技术公司 用于用全人抗cd20/cd19免疫治疗来治疗癌症的组合物和方法
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
CN121986113A (zh) 2023-07-07 2026-05-05 美国政府(由卫生和人类服务部的部长所代表) 人源化40h3抗体
AU2024295016A1 (en) 2023-07-20 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
US20260000765A1 (en) 2024-06-27 2026-01-01 Lentigen Technology, Inc. CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2536997B1 (fr) * 1982-03-11 1987-08-07 Sanofi Sa Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
GR79124B (da) * 1982-12-22 1984-10-02 Genentech Inc
ATE68703T1 (de) * 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
CA1286843C (en) * 1985-10-30 1991-07-23 Leo S. Lin Purification method for proteins
DE3650692T2 (de) * 1986-03-07 1999-04-22 Chiron Corp., Emeryville, Calif. Rekombinantes Ricin-Toxin

Also Published As

Publication number Publication date
AU596153B2 (en) 1990-04-26
EP0237297A1 (en) 1987-09-16
NO870668L (no) 1987-09-07
DK118887A (da) 1987-09-07
FI870981A0 (fi) 1987-03-05
NO870668D0 (no) 1987-02-19
FI870981A7 (fi) 1987-09-07
FI870981L (fi) 1987-09-07
AU6973887A (en) 1987-09-10
CA1308680C (en) 1992-10-13
US4689401A (en) 1987-08-25

Similar Documents

Publication Publication Date Title
DK118887A (da) Fremgangsmaade til indvinding af mikrobielt produceret, rekombinant, oploeseligt ricintoxin-a-kaede
DE3778582D1 (de) Gasumluftherd.
FI873498L (fi) Med en elastisk taetningsprofil foersedd glasskiva, i synnerhet bilglas.
FI873157L (fi) Spaerrkonstruktioner foer gas.
DK555687A (da) Fremgangsmaade til fremstilling af n,n-diaryl-urinstoffer
DK328687D0 (da) Fremgangsmaade til halogenering af ergotalkaloider i 2-stilling, saaledes halogenerede derivater og disses anvendelse
IT1217011B (it) Gruppo cuscinetto-giunto omocinetico.
DK61792D0 (da) Fremgangsmaade til fremstilling af 2-chlor-4,6-diamino-5-cyano-pyrimidin
DK3787D0 (da) Fremgangsmaade til dimerisering af lavere a-olefiner
FI861189A7 (fi) Foerstaerkningsfoerfarande och -anordning foer gas.
FI875355L (fi) Foerpackningsbehaollare med oeppningsbar, foerseglingsfoersvagad toppfoerslutning.
DE3787051D1 (de) Immunotestverfahren.
FI872815A7 (fi) Luckpanel med foerbaettrad taetningsanordning, saerskilt anvaendbar i kontainertransportfartyg.
DK97889A (da) Fremgangsmaade til fremstilling af 4,4'-dibrombiphenyl
FI862988A0 (fi) Kristallvattenfritt kalsiumglukonat med enhetlig kristallstruktur, och foerfarande foer dess framstaellning.
DK4287A (da) Polyfluoralkylthiomethyl-forbindelser, fremgangsmaade til fremstilling deraf og anvendelse af saadanneforbindelser som overfladeaktive midler
DK34888D0 (da) Fremgangsmaade til fremstilling af n,n-(dibenzohexatrienylen)urinstoffer
FI882835A7 (fi) Pneumatisk, med slagverkan, saerskilt med ett slag arbetande anordning.
DK161187A (da) 5-phenyl-5h-indenooe1,2-daapyrimidin og derivater deraf samt fremgangsmaade til fremstilling af saadanneforbindelser.
DK417787A (da) Fremgangsmaade til fremstilling af 7-oxo-4-thia-1-azabicyclo-(3,2,0)hept-2-en-derivater
FI864095A0 (fi) I berg byggt, hoegtrycksbelastat kyllager.
FI874302A7 (fi) Diaminplatina(ii)-komplexfoereningar, med en hydroxylerad 2-fenyl-indolring.
DK84987D0 (da) Kontinuerlig fremgangsmaade til fremstilling af o,o-di-la-vere-alkylchlorthiophosphat
DK350288A (da) Fremgangsmaade til fremstilling af n-epoxypropyllactamer
DK332089D0 (da) Fremgangsmaade til genindvinding af oploesningsmiddel

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment